Premium
Acquired platelet dysfunction following mithramycin therapy
Author(s) -
Ahr David J.,
Scialla Salvatore J.,
Kimball Daniel B.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197802)41:2<448::aid-cncr2820410211>3.0.co;2-u
Subject(s) - medicine , platelet , bleeding diathesis , hemorrhagic diathesis , epinephrine , coagulation , mucocutaneous zone , bleeding time , platelet aggregation , endocrinology , gastroenterology , disease
The administration of mithramycin to patients with testicular tumors has been accompanied by a hemorrhagic diasthesis, often in the absence of thrombocytopenia. Bleeding time, platelet aggregation, platelet adenine nucleotide levels, and coagulation factor assays were studied in three patients receiving mithramycin for embryonal testicular carcinomas. These studies demonstrated a drug dependent, reversible hemorrhagic diathesis associated with (1) prolongation of the bleeding time, (2) decreased platelet aggregation responses to ADP, collagen, and epinephrine, and (3) depleted platelet stores of ADP in the absence of thrombocytopenia. These abnormalities were temporally correlated with the onset of mucocutaneous bleeding in all patients.